NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 82 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $73,413 | -61.3% | 68,610 | -6.4% | 0.00% | – |
Q2 2023 | $189,821 | -25.9% | 73,290 | +16.7% | 0.00% | – |
Q1 2023 | $256,224 | -14.2% | 62,800 | +5.5% | 0.00% | – |
Q4 2022 | $298,690 | -40.9% | 59,500 | +54.1% | 0.00% | – |
Q3 2022 | $505,000 | +2.0% | 38,600 | 0.0% | 0.00% | – |
Q2 2022 | $495,000 | +17.3% | 38,600 | +39.4% | 0.00% | – |
Q1 2022 | $422,000 | -19.5% | 27,700 | -6.4% | 0.00% | – |
Q4 2021 | $524,000 | -65.2% | 29,600 | -58.6% | 0.00% | -100.0% |
Q3 2021 | $1,505,000 | +110.2% | 71,576 | +97.2% | 0.00% | – |
Q2 2021 | $716,000 | -0.3% | 36,300 | +47.0% | 0.00% | – |
Q1 2021 | $718,000 | -20.5% | 24,700 | -17.1% | 0.00% | – |
Q4 2020 | $903,000 | +82.1% | 29,800 | -4.5% | 0.00% | – |
Q3 2020 | $496,000 | -22.7% | 31,200 | -4.0% | 0.00% | – |
Q2 2020 | $642,000 | +95.1% | 32,500 | +21.7% | 0.00% | – |
Q1 2020 | $329,000 | +21.0% | 26,700 | +81.6% | 0.00% | – |
Q4 2019 | $272,000 | +50.3% | 14,700 | +12.2% | 0.00% | – |
Q3 2019 | $181,000 | – | 13,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |